{"abstract": "Pfizer said Tuesday that it had licensed the worldwide rights to a treatment for Gaucher disease, a rare genetic disorder, from Protalix Biotherapeutics, an Israeli biotechnology company.", "web_url": "https://dealbook.nytimes.com/2009/12/02/pfizer-deal-signals-a-move-into-treating-rare-diseases/", "snippet": "Pfizer said Tuesday that it had licensed the worldwide rights to a treatment for Gaucher disease, a rare genetic disorder, from Protalix Biotherapeutics, an Israeli biotechnology company.", "lead_paragraph": "The world\u2019s largest drug company is thinking small. Pfizer said Tuesday that it had licensed the worldwide rights to a treatment for Gaucher disease, a rare genetic disorder, from Protalix Biotherapeutics, an Israeli biotechnology company, The New York Times\u2019s Andrew Pollack writes.", "source": "The New York Times", "multimedia": [], "headline": {"main": "Pfizer Deal Signals Move Into Rare Diseases", "kicker": "DealBook", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [], "pub_date": "2009-12-02T10:01:02+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Dealbook", "person": [{"firstname": "Dealbook", "middlename": null, "lastname": "", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "", "_id": "nyt://article/ca56c731-9f02-5806-bbe7-a378b35b06da", "word_count": 700, "uri": "nyt://article/ca56c731-9f02-5806-bbe7-a378b35b06da"}